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treatment option as compared with escitalopram,sertraline, and venlafaxine in 
a matrix comparator, with regard to side effects especially sexual dysfunction, 
agomelatine should be considered as the most cost-effective option for treat-
ment of depression.
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Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia and can reduce inpatient 
stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting 
injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment 
of schizophrenia in Germany. The study aims at estimating, based on a previously 
published model, the cost-effectiveness of paliperidone long-acting injections com-
pared to other common antipsychotic treatment strategies in patients diagnosed 
with schizophrenia in Germany. MethOds: A Markov decision analytic model was 
adapted to the German health care system. The model considers the cost-effective-
ness for PLAI as a maintenance treatment for patients with schizophrenia from the 
payer perspective. The patients transition between eight health states on a monthly 
basis over a 5-year time horizon. As therapeutic strategies PLAI, quetiapine, risperi-
done long-acting injections (RLAI), oral olanzapine, oral risperidone, zuclopenthixol 
decanoate, olanzapine long-acting injections (OLAI), oral typical and oral atypical 
were compared. Probability of relapse, level of adherence, side effects and treatment 
discontinuation were derived from the Swedish original model. Input factors regard-
ing resource use and costs were estimated and adjusted for the German health care 
system. A probabilistic sensitivity analyses using cost-effectiveness scatter plots 
was performed to visualize the robustness of the results. Results: In base case 
scenario PLAI is superior to RLAI in gained quality adjusted life years (QALYs) and 
avoided relapses. Relative to all other treatment strategies PLAI is more effective 
with regard to gained QALYs and avoided relapses but results in higher treatment 
costs over a 5-year horizon in base case scenario. The results were tested in proba-
bilistic sensitivity analyses cOnclusiOns: PLAI dominates RLAI and compared to 
the other treatment strategies PLAI has shown to be more effective but results in 
higher costs in base case scenario.
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Depression is present in 10% of patients attending primary care services and is 
generally not identified. In Mexico it is estimated a prevalence of 12% to 20% among 
adults between 18-65 years old. Up to 75% of patients treated with a selective inhibi-
tor of serotonin reuptake (SSRIs) are not responding adequately. Atypical antipsy-
chotics are an effective alternative for these patients. Objectives: To evaluate the 
cost-effectiveness (CE) of extended release (XR) quetiapine as adjunctive therapy 
(AT) in patients with major depressive disorder (MDD) that doesn’t respond to 
antidepressant treatment (AD), compared with other antipsychotics listed in the 
Mexican Formulary (aripiprazole and olanzapine). MethOds: A Markov model 
was developed to perform and incremental analysis with weekly cycles during 
eight weeks time horizon, based on the meta-analysis developed by Komossa et.al 
in 2010. Health states: remission, relapse and discontinuation of treatment. The 
model estimates the remission time gained (RG) by each AT alternative. The analy-
sis was done from society perspective, considered direct costs, and reported in 
2013 US dollars. Results: Patients with AT with quetiapine XR had 1.83 weeks 
of RG, while patients under aripiprazole and olanzapine obtained 1.5 and 1.72 
weeks of RG, respectively. Quetiapine XR compared to olanzapine generated an 
additional cost per patient of $94.70, with additional RG of 0.11 weeks and ICER 
of $881.73. Quetiapine XR dominated extendedly to aripiprazole. Robustness of 
results were confirmed by additional deterministic and probabilistic sensitivity 
analysis. cOnclusiOns: The use of quetiapine XR as adjuvant treatment for non-
responders patients is a cost-effective compared to aripiprazole and olanzapine, 
and could be considered as an option in an institutional setting.
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Objectives: Sexual dysfunctions (SD) is a common adverse event of antidepressants. 
It has a lasting impact on quality of life and is associated with an increased risk of 
early treatment discontinuation. Using an open-source Discrete Event Simulation 
model (https://open-model-mdd.org/), we performed a cost-effectiveness analysis 
comparing alternative sequences of treatments, to determine whether an antidepres-
sant with moderate efficacy and reduced risk of SD should be positioned before or 
after a treatment with high efficacy and average risk of SD. MethOds: The model 
used was designed to simulate costs and QALYs in cohorts of patients with major 
depressive disorder (MDD), under alternative treatment strategies over 5 years. 
Each strategy consisted of up to 4 lines of treatment, with possibility to switch to 
different drugs when a patient experienced adverse events or lack of efficacy. We 
between 2006 and 2012. Results: Our findings indicate that in the assessed time 
period an average yearly amount of approximately € 5,5 million (calculation based 
on yearly average EUR/HUF exchange rates) is spent on second generation antip-
sychotics, which are prescribed and purchased with reimbursement but finally 
not used by the patients due to early medication discontinuation. Based on our 
calculations, the average yearly treatment costs of antipsychotics increased from 
€ 612 (2006) to € 974 (2012) per patient in the assessed time period. The analysis of 
the NHIF database resulted, that the average yearly expenditure on different antip-
sychotics, varied between € 173 and € 2420 per patient. cOnclusiOns: All-cause 
medication discontinuation is a major concern in the treatment of schizophrenia 
both from a clinical and both from a health economic perspective. In order to 
ensure resources are spent cost-effectively, it is crucial to identify methods which 
can improve treatment continuation and adherence of schizophrenia patients 
in the future.
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Objectives: To compare the effect of adjunctive therapy with pregabalin versus 
usual care (UC) on health care costs and clinical and patients consequences in 
Generalized Anxiety Disorder (GAD) subjects with partial response (PR) to previous 
SSRI course in medical practice in Spain. MethOds: Post-hoc analysis of patients 
with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. 
PR was defined as a Clinical-Global-Impression scale score > 3 and insufficient 
response with persistence of anxiety symptoms > 16 in the Hamilton-Anxiety scale. 
Two groups (based on psychiatrist judgment) were analyzed 1) adjunctive therapy 
(AT) with pregabalin (150-600 mg/day) to existing therapy; or 2) usual care (switching 
to a different SSRI or adding another anxiolytic different than pregabalin). Costs 
estimation used year-2009 prices for GAD related health care resources utilization. 
Consequences were a health profile based on the combination of psychiatrist-based-
measurements [HAM-A, CGI and Montgomery-Asberg-Depression-Rating (MADRS) 
scales], and patient-reported-outcomes [sleep (MOS-sleep), disability (WHO-DAAS 
II) and quality-of-life/quality-adjusted-life-year gain (EQ-5D)]. Changes in both 
health care costs and scale scores were compared separately at end-of-trial visit 
by a general-linear-model with covariates. Results: Four-hundred-eighty-six 
newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) 
and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with signifi-
cantly higher mean (95% CI) score reductions vs. UC in HAM-A [-14.9(-15.6;-14.2) vs. 
-11.2(-12.2;-10.2), p< 0.001] and MADRS [-11.6(-12.2;-10.9) vs. -7.8(-8.7;-6.8), p< 0.001]. 
Changes in all patient-reported-outcomes favored significantly patients receiving 
pregabalin, including QALY gain; 0.13(0.12;0.14) vs. 0.09(0.07;0.10), p< 0.001. Health 
care costs were significantly reduced in both cohorts yielding similar 6-month costs; 
€ 1543 (1375;1711) UC and € 1497 (1380;1614) pregabalin, p= 0.661. The effect of sex on 
costs and consequences were negligible. cOnclusiOns: In medical practice, GAD 
patients with PR to SSRI experienced greater consequences improvements with 
adjunctive therapy with pregabalin versus UC, without increasing health care cost. 
The effect of pregabalin was independent of patient gender.
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Objectives: To compare cost-effectiveness of agomelatine versus an escitalo-
pram-sertraline-venlafaxine matrix comparator. MethOds: A DESM describes 
course of depressive disorders with acute , continuation, and maintenance treat-
ment of depression in Thai setting for 24 months. A sample of 250,000 patients 
with 100 simulations were assumed with Exigo® model. Antidepressants were 
analyzed for treatment of episodes(12-24 weeks),continuation phase(6-9 months), 
maintenance phase over 2 years follow-up. Data inputs included Thai data on 
disease parameters; Cost included antidepressants, drugs for insomnia, sexual 
side-effects, cognitive behavioral therapy(CBT), electroconvulsive therapy(ECT) 
and mean cost of psychiatric visits. Impact measures were derived from a sys-
temic review. Results were presented as cost(Thai-Baht currency-THB) per Life-
Year-Remission(LYR) averted and Quality-Adjusted Life Year(QALY) compared with 
branded antidepressants in the matrix comparator (46%escitalopram, 33%ser-
traline, 21%venlafaxine). Model simulation initiated with either agomelatine 
25mg or comparators(escitalopram10mg,sertraline100mg,venlafaxine 150mg 
by random selection). Relapse cases required dose increase fro each antidepres-
sant, addition of CBT and ECT. Data on impact of treatment on quality of life in 
patients free from relapse, sexual side effects, insomnia were taken from cochrane 
database. Results: During 24 months, patients treated with agomelatine cost 
15,814.2THB and 20,232.0THB per LYR and QALY gains, whereas with compara-
tor cost 17,999.6THB and 23,431.7THB per LYR and QALY gains. As a result, the 
incremental cost-effectiveness ratio(ICER) shows that agomelatine is the most 
cost-effective antidepressant for episodic treatment with/without continua-
tion or maintenance phase, its cost being lower than comparator by 153,283 and 
83,645 THB per LYR and QALY. These results were robust, probability sensitiv-
ity analysis suggested that agomelatine was effective for a willingness-to-pay 
of 300,000THB,95%CI of -146,120.4 to -179,651.0THB per QALY, with probability of 
> 0.90. cOnclusiOns: Based on the model, agomelatine is the most cost-effective 
